Chongqing Lummy Pharmaceutical (300006.SZ) plans to participate in the establishment of the Shengquan Baijie Fund.

Chongqing Lummy Pharmaceutical (300006.SZ) announced that recently, the company has signed a partnership agreement with Xi'an Wo Jie Private Equity Fund Management Co., Ltd. (referred to as "Xi'an Wo Jie" "fund manager" "executive transaction partner"), Sansure Biotech Inc. Technology Co., Ltd., etc., titled "Guangzhou Shengquan Baijie Entrepreneurship Investment Fund Partnership Enterprise (Limited Partnership) (Fundraising) Partnership Agreement". The parties intend to jointly contribute to establish Guangzhou Shengquan Baijie Entrepreneurship Investment Fund partnership enterprise (limited partnership) (tentatively named "Shengquan Baijie fund"). The total scale of funds raised by the partnership enterprise is 150 million RMB, with the company as a limited partner subscribing and contributing 5 million RMB with its own funds, accounting for 3.33% of the subscribed capital. Investment areas: mainly focusing on innovative biopharmaceuticals, medical devices, in vitro diagnostics, and other related fields in the life and health sector, and the investment proportion in the above-mentioned industry sectors shall not be less than 60% of the total actual paid-in capital of the fund. The fund will mainly target strategic emerging industries and future industries in Guangzhou City, and the proportion of investment in seed and angel stage projects in Guangzhou City shall generally not be less than 1 times the actual paid-in capital of the Guangzhou Angel Investment Fund entrepreneurship investment partnership enterprise (limited partnership). By investing in the Shengquan Baijie fund, the company will leverage the project resources and investment management capabilities of professional investment institutions to invest in early and growth-stage innovative biopharmaceutical enterprises that meet the requirements, accelerate the layout of strategic points with high barriers and high growth in the pharmaceutical and health industry chain, and increase the company's investment opportunities in the biopharmaceutical field, enrich the product line, enhance profitability, and improve core competitiveness.